Jakafi

Incyte Drug Misses Endpoint in COVID-Respiratory-Distress Trial
Incyte Drug Misses Endpoint in COVID-Respiratory-Distress Trial
TheStreet.com
Incyte
Jakafi
clinical trials
COVID-19
ARDS
Flag link:
Jakafi failed the primary endpoint in a Covid-19 study. But Incyte is still going to FDA with a compassionate use pitch
Jakafi failed the primary endpoint in a Covid-19 study. But Incyte is still going to FDA with a compassionate use pitch
Endpoints
Jakafi
Incyte
COVID-19
clinical trials
Flag link:
FDA to quickly review Incyte’s Jakafi in chronic GVHD
FDA to quickly review Incyte’s Jakafi in chronic GVHD
Pharmaforum
FDA
Incyte
Jakafi
graft vs host disease
Flag link:
Novartis/Incyte draw blank with Jakafi in COVID-19
Novartis/Incyte draw blank with Jakafi in COVID-19
Pharmaforum
Novartis
Incyte
Jakafi
COVID-19
clinical trials
Flag link:
Novartis, Incyte's Jakafi boosts its case in graft-versus-host disease with another phase 3 win
Novartis, Incyte's Jakafi boosts its case in graft-versus-host disease with another phase 3 win
Fierce Pharma
Novartis
Incyte
Jakafi
clinical trials
COVID-19
cytokine storm
graft vs host disease
Flag link:
Incyte, Novartis launch drug study to treat coronavirus complication
Incyte, Novartis launch drug study to treat coronavirus complication
Marketwatch
Incyte
Novartis
cytokine storm
COVID-19
clinical trials
Jakafi
Flag link:
Incyte to Test Its Cancer Drug Jakafi as a Treatment for COVID-19
Incyte to Test Its Cancer Drug Jakafi as a Treatment for COVID-19
Motley Fool
cancer
COVID-19
Incyte
Jakafi
Flag link:
Can Jakafi hit $3B? Incyte thinks so—and it's got other launches on the way
Can Jakafi hit $3B? Incyte thinks so—and it's got other launches on the way
Fierce Pharma
Incyte
Jakafi
pemigatinib
Flag link:
Is IBD 50 Drugmaker Incyte Stock On The Cusp Of Innovation-Fueled Growth Spurt?
Is IBD 50 Drugmaker Incyte Stock On The Cusp Of Innovation-Fueled Growth Spurt?
Investors Business Daily
Incyte
Jakafi
innovation
Flag link:
Incyte's cash cow Jakafi chugs along with positive frontline results for GVHD
Incyte's cash cow Jakafi chugs along with positive frontline results for GVHD
Endpoints
Incyte
FDA
graft vs host disease
Jakafi
Flag link:
This Could Be a Big Year for Incyte
This Could Be a Big Year for Incyte
Motley Fool
Incyte
Jakafi
blood cancers
Flag link:
Incyte (INCY) Receives FDA Nod for Label Expansion of Jakafi
Incyte (INCY) Receives FDA Nod for Label Expansion of Jakafi
Yahoo/Zacks.com
FDA
Incyte
Jakafi
graft vs host disease
Flag link:
Incyte Down as FDA Extends Review Period of Jakafi for GVHD
Incyte Down as FDA Extends Review Period of Jakafi for GVHD
Yahoo/Zacks.com
Incyte
FDA
Jakafi
graft vs host disease
Flag link:
FDA Grants Priority Review for Ruxolitinib (Jakafi) for Acute Graft-Versus-Host Disease
FDA Grants Priority Review for Ruxolitinib (Jakafi) for Acute Graft-Versus-Host Disease
CP Wire
FDA
Incyte
Novartis
Jakavi
Jakafi
graft vs host disease
Flag link:
FDA Grants Priority Review for Ruxolitinib (Jakafi) for Acute Graft-Versus-Host Disease
Incyte
graft vs host disease
Novartis
Jakafi
Flag link:
Incyte preps Jakafi expansion into graft-versus-host disease
Incyte preps Jakafi expansion into graft-versus-host disease
Biopharma Dive
Incyte
Jakafi
graft vs host disease
Flag link:
Biotech Firm Incyte Finds The Right Chemistry For Success
Biotech Firm Incyte Finds The Right Chemistry For Success
Forbes
Incyte
biotech
Jakafi
Flag link:
Does Incyte Have The Best Cancer Portfolio Among Mid-Cap Biotechs?
Does Incyte Have The Best Cancer Portfolio Among Mid-Cap Biotechs?
Barron's
Incyte
epacadostat
olumiant
Jakafi
immuno-oncology
Flag link:
What Were Incyte’s Revenue Streams in 3Q16?
What Were Incyte’s Revenue Streams in 3Q16?
Market Realist
Incyte
Jakafi
Iclusig
Flag link:
Gilead Fails to Beat Incyte’s Jakafi Drug
Gilead Fails to Beat Incyte’s Jakafi Drug
Investopedia
Gilead Sciences
Jakafi
Incyte
momelotinib
myelofibrosis
Flag link:

Pages